Breaking News

IASO Bio’s Nanjing Mfg. Facility Licensed for CAR-T Cell Therapies

The cell production workshop designed according to cGMP requirements has the capacity of producing 3,000 batches of CAR-T cell products per year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

IASO Biotherapeutics, a clinical-stage biopharmaceutical company developing and manufacturing innovative cell therapies and antibody products, was granted a drug manufacturing license by the Medical Products Administration of Province Jiangsu (JSMPA) for its commercial manufacturing facility in Nanjing following a successful comprehensive inspection.   The cell production workshop, as a core facility area, is designed in the form of a workstation according to the cGMP requirements and NMPA/EMA...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters